{"id":"W2152840183","doi":"10.1093/neuonc/nop017","title":"A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas","year":2009,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Center for Research Resources; National Cancer Institute","keywords":"Erlotinib; Medicine; Rash; Toxicity; Pharmacokinetics; Gastroenterology; Diarrhea; Pharmacology; Internal medicine; Chemotherapy; Phases of clinical research; Oncology; Cancer; Epidermal growth factor receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000997436,0.0001851058,0.0004595621,0.000256626,0.00003585757,0.000009865801,0.00003471697,0.0001075719,0.000007075141],"category_scores_gemma":[0.00006216299,0.0001294877,0.00004022394,0.0002123961,0.00008524243,0.00007026722,0.00001536644,0.000108851,7.406219e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006829431,"about_ca_system_score_gemma":0.00007891768,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001349518,"about_ca_topic_score_gemma":0.00002628724,"domain_scores_codex":[0.9988089,0.00009240055,0.0003517889,0.000321098,0.0001972807,0.0002285071],"domain_scores_gemma":[0.9992406,0.0001472531,0.0002512524,0.0001400526,0.0000867726,0.0001340787],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.2054871,0.01983836,0.08452615,0.00002944137,0.0001164806,0.000871049,0.001558909,0.000001495545,0.04011722,0.00008360424,0.00007317699,0.647297],"study_design_scores_gemma":[0.4583057,0.2090711,0.3053593,0.0001206479,0.0001445571,0.0001101135,0.00007211017,0.0001440078,0.02553056,0.00003210525,0.0009378902,0.0001718962],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.996646,0.0003682872,7.72054e-7,0.0009226976,0.0001080895,0.001857132,0.00001834035,0.00001741523,0.00006122923],"genre_scores_gemma":[0.9993511,0.0001253909,0.0002105507,0.0001565455,0.00004206555,0.00007676226,0.00002388287,0.00001323402,4.664541e-7],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6471251,"threshold_uncertainty_score":0.5280353,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01769246670536518,"score_gpt":0.3037294282658909,"score_spread":0.2860369615605257,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}